AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Drug maker AstraZeneca PLC (LSE:AZN)'s fourth quarter numbers marginally undershot consensus as it felt the impact of declining sales of its Covid vaccine. Total revenues for the three months ended December 31 were US$11.2bn, around $100 million shy of consensus.

AstraZeneca PLC modestly undershoots consensus in the fourth quarter; targeting low double digit sales growth this year

AstraZeneca on Thursday posted fourth-quarter revenue just shy of analyst estimates, with slightly lower-than-expected sales of its best-selling oncology and rare blood disorder drugs.

AstraZeneca Q4 revenue just shy of analyst estimates

Unilever

British American Tobacco

A pretty busy DAY for London blue-chip share followers. Top of the table is AstraZeneca PLC (LSE:AZN), biggest company in the FTSE 100 over Shell by a few billion.

AstraZeneca, BAT, Unilever and Compass lead a busy Thursday

AstraZeneca PLC said Tuesday that Forxiga has been approved in the European Union for the treatment of symptomatic chronic heart failure.

AstraZeneca says Forxiga approved in EU for heart failure

Amgen

1Life Healthcare

Pfizer

Third Harmonic Bio Inc

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks That May Rally - AstraZeneca (NASDAQ:AZN), Amgen (NASDAQ:AMGN)

Akebia Therapeutics

FibroGen

GlaxoSmithKline

GSK announces the FDA approval of daprodustat for the treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis for at least four months.

GSK's Daprodustat Drug for Anemia Due to CKD Gets FDA Nod

AstraZeneca PLC (LSE:AZN) is poised to release its full-year results for 2022 on February 9, with shareholders hoping for the pharmaceutical giant to beat upgraded guidance outlined in November 2022 following strong year-to-date performance. Total revenues are expected to increase by a low twenties percentage, with a core earning-per-share increase of a high-twenties to low-thirties percentage.

AstraZeneca: Will pharma giant beat revenue expectations?

WILMINGTON, Del.--( BUSINESS WIRE )--AstraZeneca and Amgen's TEZSPIRE® (tezepelumab-ekko) has been approved in the US for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma. TEZSPIRE is the only biologic approved for severe asthma with no phenotype (e.g. eosinophilic or allergic) or biomarker limitation within its approved label.1

TEZSPIRE® approved for self-administration in the US with a new pre-filled pen

Medtronic

Merck

These healthcare titans are poised for a strong showing in 2023 and beyond.

3 No-Brainer Dividend Stocks to Buy Hand Over Fist in 2023

Novo Nordisk

Sanofi

The court ruled that drugmakers can limit their shipments of federally-discounted drugs to pharmacies, in a blow to hospitals and clinics.

U.S. Appeals Court Sides With Drugmakers on Discount Program

TOKYO & BASKING RIDGE, N.J.--( BUSINESS WIRE )--Daiichi Sankyo (TSE: 4568) today announced that the first patient has been dosed in the global, randomized TROPION-Lung07 phase 3 trial evaluating datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum chemotherapy, in patients with previously untreated advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with PD-L1 expression less than 50% (TPS

TROPION-Lung07 Phase 3 Trial Initiated to Evaluate Datopotamab Deruxtecan in Combination with Pembrolizumab in Patients with Previously Untreated Metastatic Non-Small Cell Lung Cancer

AstraZeneca's (AZN) Evusheld is no longer authorized for use in the United States after laboratory data showed that it does not neutralize Omicron subvariants.

FDA Pulls EUA Granted to AstraZeneca's (AZN) Evusheld

BioNTech SE

CVS Health

Gilead Sciences

LHC Group

Leap Therapeutics

Moderna

Neovasc

Signify Health

Shockwave Medical

UnitedHealth Group

Mergers and acquisitions are a normal part of business, but 2023 has already presented many opportunities across the biotech industry. The M&A surge seems to be driven by two major transactions: the $6 billion sale of LHC Group Inc. (Nasdaq: LHCG) to UnitedHealth (NYSE: UNH) and the $8 billion sale of Signify Health Inc. (NYSE: SGFY) to CVS Health Co. (NYSE: CVS).

Mergers and Acquisitions in 2023 Off To A Strong Start

Chevron

Lockheed Martin

Newmont Mining

AT&T

Vale S.A.

Walmart

A key to successful retirement planning or wealth building is to start early. One critical component of investing is to secure stable cash flows.

7 Dividend Stocks to Buy for a Stable Income Stream

Many take Evusheld as an additional layer of protection because the vaccines do not trigger a strong immune response for them.

FDA withdraws Covid antibody treatment Evusheld because it's not effective against 93% of subvariants

AstraZeneca AZN, -1.32% AZN, -1.54% said Thursday that the Food and Drug Administration is no longer allowing healthcare providers to prescribe Evusheld, a therapy authorized for pre-exposure prophylaxis of COVID-19, citing its lack of effectiveness against the currently circulating variants. The company said Evusheld does not neutralize subvariants like XBB.1.5, BQ.1, and BQ.1.1 — the three most common strains of the virus circulating in the U.S., according to the Centers for Disease Control and Prevention.

AstraZeneca's preventive COVID therapy no longer effective against current variants

TOKYO & MUNICH--( BUSINESS WIRE )--Daiichi Sankyo (TSE: 4568) and AstraZeneca's (LSE/STO/Nasdaq: AZN) ENHERTU® (trastuzumab deruxtecan) has been approved in the European Union (EU) as monotherapy indicated for the treatment of adult patients with unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy.

ENHERTU® Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast Cancer

Thermo Fisher Scientific

CARLSBAD, Calif.--( BUSINESS WIRE )--As part of a global, multiyear agreement, Thermo Fisher Scientific today announced it is working with AstraZeneca to develop a solid tissue and blood-based companion diagnostic (CDx) test for Tagrisso (osimertinib). The CDx will help identify patients with non-small cell lung cancer (NSCLC) who may be eligible for treatment with Tagrisso by identifying tumors that exhibit epidermal growth factor receptor (EGFR) alterations including exon 21 L858R mutations, exon 19 deletions or T790M mutations.

Thermo Fisher Scientific Partners with AstraZeneca to Develop Solid Tissue and Blood-Based Companion Diagnostic Test for Tagrisso

WILMINGTON, Del.--( BUSINESS WIRE )--AstraZeneca is commencing today, through a subsidiary, a tender offer to purchase all outstanding shares of CinCor Pharma, Inc. (CinCor), for $26 per share in cash at closing, plus a non-tradable contingent value right of $10 per share in cash payable upon a specified regulatory submission for a baxdrostat product. On 9 January 2023, AstraZeneca announced that it had entered into a definitive agreement to acquire CinCor. Following the successful closing of the tender offer, CinCor will become a subsidiary of AstraZeneca.

AstraZeneca Begins Tender Offer to Acquire CinCor Pharma, Inc.

AIM ImmunoTech Inc

AIM ImmunoTech Inc (NYSE:AIM) (AIM) announced that it has entered into an external sponsored collaborative clinical research agreement with AstraZeneca and Erasmus Medical Center in the Netherlands that will evaluate the potential of AIM's Ampligen (rintatolimod) in combination with AstraZeneca's Imfinzi (durvalumab) for the treatment of pancreatic cancer.  Ampligen is AIM's dsRNA drug currently being developed for globally important cancers.

AIM ImmunoTech shares rise on news of pancreatic cancer research partnership with AstraZeneca and Erasmus Medical Center

Bayer AG

Eli Lilly

These big pharmaceuticals are poised for back-to-back big years.

3 Growth Stocks Poised for Huge Gains in 2023

AstraZeneca AZN, +0.99% AZN, -0.27% said Wednesday that the Food and Drug Administration approved a new therapy that can be used to treat or prevent bronchoconstriction in adults with asthma. Thee company said Airsupra is a first-in-class treatment that is administered in an inhaler using a combination of albuterol and budesonide.

FDA approves AstraZeneca's new treatment for people with asthma

AstraZeneca stock edged into breakout territory on Tuesday, a day after announcing its $1.8 billion plan to acquire CinCor Pharma. The post AstraZeneca Stock Nabs Breakout After $1.8 Billion CinCor Buyout appeared first on Investor's Business Daily.

AstraZeneca Stock Nabs Breakout After $1.8 Billion CinCor Buyout

AstraZeneca's (AZN) CinCor Pharma buyout is going to add blood pressure drug baxdrostat to its cardiorenal pipeline.

AstraZeneca (AZN) Set to Acquire CinCor Pharma for $1.3B

AbbVie

Bristol-Myers

Johnson & Johnson

Novartis

Roche Holding AG

The pipeline is the heart of a drug discovery company. As such, analyzing the health of a pipeline can lead to suggestions about future performance.

Ranking The Top 10 Pharmaceuticals By Pipeline

News for AstraZeneca Stock (AZN)